Fig. 1

Time-course and relationship with CEBPB expression. Isometric strength (nm torque, ± SEM) decreases from baseline (a, *p < 0.05, n = 16) post-damage. Plasma creatine kinase activity (U/l, at 37 °C, ± SEM) increases from baseline (b, *p < 0.05, n = 16), peaking on day 4. Mean CEBPB blood transcript expression change (CEBPB quantification refers to CEBPB transcript expression relative to levels of the endogenous control gene PPIA and normalised to the mean CEBPB level over all samples, ± SEM) is higher at day 2 in n = 9 subjects with >10,000 peak plasma creatine kinase activity (c, *p = 0.006). d Shows the participants' change in CEBPB expression (day 2 minus baseline) and peak CK levels